• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec.

作者信息

Che Yonglu, Abou-Taleb Farah, Reddy Sunil A, Chang Anne L S

机构信息

Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California.

出版信息

Dermatol Surg. 2025 Mar 3;51(7):730-731. doi: 10.1097/DSS.0000000000004591.

DOI:10.1097/DSS.0000000000004591
PMID:40028913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12188781/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6135/12188781/17bd31fbb8b2/ds-51-730-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6135/12188781/17bd31fbb8b2/ds-51-730-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6135/12188781/17bd31fbb8b2/ds-51-730-g001.jpg

相似文献

1
Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec.瘤内注射Talimogene Laherparepvec后难治性转移性基底细胞癌的临床改善
Dermatol Surg. 2025 Mar 3;51(7):730-731. doi: 10.1097/DSS.0000000000004591.
2
Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.德国 IIIB 期至 IVM1a 期黑色素瘤患者中替莫唑胺拉帕替尼的真实世界应用：回顾性图表审查和医生调查。
Adv Ther. 2019 Jan;36(1):101-117. doi: 10.1007/s12325-018-0850-6. Epub 2018 Dec 7.
3
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.替莫唑胺胶囊：不可切除的转移性黑色素瘤的治疗选择。
BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y.
4
A practical guide to the handling and administration of talimogene laherparepvec in Europe.欧洲塔利莫吉拉帕里韦克处理与给药实用指南
Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017.
5
Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.替西罗莫司与伊匹木单抗和维莫非尼治疗转移性黑色素瘤患者的间接治疗比较
Adv Ther. 2016 Apr;33(4):643-57. doi: 10.1007/s12325-016-0313-x. Epub 2016 Mar 15.
6
Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec.瘤内溶瘤免疫疗法Talimogene Laherparepvec的药学操作规范
Hosp Pharm. 2018 Oct;53(5):296-302. doi: 10.1177/0018578717749926. Epub 2018 Jan 10.
7
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
8
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.最终分析 OPTiM：替莫唑胺联合粒细胞巨噬细胞集落刺激因子对比单用替莫唑胺治疗不能手术的 III-IV 期黑色素瘤的随机 III 期临床试验。
J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.
9
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.对于在免疫检查点抑制剂和BRAF抑制剂治疗后疾病进展的黑色素瘤患者，talimogene laherparepvec的潜在临床及免疫治疗效用。
Melanoma Res. 2018 Jun;28(3):250-255. doi: 10.1097/CMR.0000000000000444.
10
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.替利莫吉因拉赫帕瑞韦克用于不可切除的IIIB-IVM1c期黑色素瘤患者的扩大可及性方案的IIIb期安全性结果
Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399.

本文引用的文献

1
Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec.经瘤内注射talimogene laherparepvec后，与耳周皮肤鳞状细胞癌相关的颈部转移淋巴结消退
JAAD Case Rep. 2024 Feb 18;46:92-94. doi: 10.1016/j.jdcr.2024.02.008. eCollection 2024 Apr.
2
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.非黑色素瘤皮肤癌治疗的最新进展：PD-1 抑制剂在基底细胞癌和皮肤鳞状细胞癌中的应用。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005082.
3
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
随机、双盲、安慰剂对照、全球 III 期试验：替莫唑胺联合替莫唑胺治疗晚期黑色素瘤。
J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23.
4
Complete and Sustained Remission of Metastatic Cutaneous Squamous Cell Carcinoma in a Liver Transplant Patient Treated With Talimogene Laherparepvec.接受Talimogene Laherparepvec治疗的肝移植患者转移性皮肤鳞状细胞癌实现完全且持续缓解
Dermatol Surg. 2021 Jun 1;47(6):820-822. doi: 10.1097/DSS.0000000000002739.